Phase II studies, including the LUX-Bladder 1 trial (NCT02780687) and NCI-MATCH EAY131 basket trial, evaluated treatment with afatinib, a pan-HER TKI, and demonstrated mixed results in patients with HER2/3 mutations, while no responses were seen in 42 patients expressing HER1 (EGFR) mutations [59,65,66,67]. The gene discussed is EGFR; the disease is urogenital neoplasm.